预约演示

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

2023-07-26

临床3期临床结果

AbbVie has announced that the first patient has been dosed in a late-stage study of its selective JAK inhibitor, Rinvoq (upadacitinib), in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS).

AbbViea long-term skin condition that causes painful bumps, nodules or abscesses that can leak fluJAK inhibitor JAKand lead to Rinvoqngupadacitinib hidradenitis suppurativa (HS)

An estimated 1% of the global population is affected by HS, but patientabscesseserience increasing disease severiscarringymptoms for as long as ten years before receiving an accurate diagnosis.

"There is no cure for HS, and there are limited treatment options, making further study of this disease critical to better understand its impact and help meet patients' unmet needs,” AbbVie said in a statement.

The company's phase 3 Step-Up HS trial will aim to enrol about 1,300 patients who have failed anti-TNF therapy and/or one approved non-anti-TNF inhibitor therapy for the condition. ThAbbVietients will be randomised to receive Rinvoq or placebo.

The study's primary endpoint will measure the percentage of participants achieving at least a 50% rTNFction in the total abscess and inanti-TNF inhibitor TNFry nodule count with no increase in abscess count or draining fistula count relativRinvoqaseline at week 16, the company outlined.

The launch follows the completion of a mid-stage study of Rinvoq in patients with moderate-to-severe HS.abscess inflammatory nodule abscess

The results, which were presented at this year's American Rinvoqy of Dermatology Annual Meeting in March, showed that a higher proportion of Rinvoq-treated patients achieved at least a 50% reduction in abscess and inflammatory nodule count without an increase in abscess or draining fistula count compared to those receiving placebo.

Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, AbbVie, said: "HS is a chronic, inflammaRinvoqisease that often leads to irreversible skin damage andabscesse paiinflammatory nodule abscess

"Leveraging our proven expertise in immunology and experience in HS, we continue to drive innovation AbbViersue advancement of care in patient populations with difficult-to-treat immune-mediated diseases that hapainimited therapeutic options.”

Rinvoq is already approved to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative cimmune-mediated diseasesitis.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构